Novartis's Farydak Enters EU As First-In-Class Myeloma Therapy
This article was originally published in Scrip
Novartis AG's histone deacetylase (HDAC) inhibitor Farydak (panobinostat; also known as Faridak) has secured approval in Europe for the treatment of multiple myeloma – making it the first drug of this class to reach the European market.
You may also be interested in...
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2022’s meeting of industry leaders, investors and technology creators.
Clive Dix was awarded Scrip’s Lifetime Achievement honor jointly with his long-term colleague and friend Dame Kate Bingham in December 2021. With more than 30 years’ experience in pharma and biotech, Dix has seen the industry evolve and take on many challenges. He spoke to In Vivo about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.